Acelot is a development stage biopharmaceutical company focused on therapies for Alzheimer’s Disease and central nervous system disorders. It is headquartered in Santa Barbara and started its development work in 2011 based on cheminformatics technology developed at the University of California, Santa Barbara. Our revolutionary JPS technology allows us to develop on-target therapies with a high degree of therapeutic predictability.
Acelot’s current drug discovery pipeline comprises several novel compound families for the amyloid beta oligomer and LXR target for the treatment of Alzheimer’s disease. These compounds have been validated in a number of in-vitro assays to date.
Please contact us if you are interested in partnering for any of our projects.
